Express Pharma
Home  »  Latest Updates  »  Lasa gets environmental clearance for benzimidazole derivatives capacity expansion at Khed facility

Lasa gets environmental clearance for benzimidazole derivatives capacity expansion at Khed facility

Lasa’s total volumetric capacity to increase by ~60 per cent to 6,800 TPA

0 119
Read Article

API manufacturer, Lasa Supergenerics announced that it has received the ‘environmental clearance’ from the State Environment Impact Assessment Authority (SEIAA) for expanding its ‘benzimidazole derivatives’ capacity at the company’s manufacturing facility at Khed, Maharashtra.

The proposed expansion will require only a de-bottlenecking CAPEX as the company already has the necessary infrastructure and machinery in place and was awaiting environmental clearance to operationalise the assets.

Post the successful de-bottlenecking, the company’s volumetric capacity will increase by 2,500 TPA (rated capacity by 650 TPA) taking the company’s total volumetric capacity to 6,800 TPA (total rated capacity of 2,500 TPA). The expanded capacity will be used to manufacture the benzimidazole derivatives (such as Albendazole, Fenbendazole and others). The enhanced capacity is expected to be commissioned in Q3 FY21 and likely to contribute to the top-line from Q4 FY21 onwards.

Commenting on this development, Dr Omkar Herlekar, Chairman and MD, Lasa Supergenerics said, “Receiving the Environmental Clearance for capacity expansion is a significant milestone for fulfilling Lasa’s expansion plans. Now, we will be able to increase our manufacturing capacity from existing 4,300 TPA to 6,800 TPA post the successful commissioning of the proposed expansion at our state-of-the-art WHO-GMP certified API manufacturing facility in Khed, Maharashtra. Furthermore, as we already have the necessary infrastructure and machinery in place, the proposed expansion will require only a de-bottlenecking CAPEX of approximately Rs 3 crores. The expanded capacity is expected to be commissioned in Q3 FY21 and likely to start contributing to the overall revenue from Q4 FY21 onwards. The enhanced capacity at peak utilisation can potentially generate sizeable incremental revenue.”

Leave A Reply

Your email address will not be published.

 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
close-image
Want to know more about "Omic's" and it's relevance?
Register Now
close-image